Regeneron Pharmaceuticals (REGN) Inventory Average (2014 - 2026)

Regeneron Pharmaceuticals has reported Inventory Average for 13 years, with the latest figure at $3.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Inventory Average changed 0.39% year-over-year to $3.2 billion; the trailing twelve-month figure through Mar 2026 stood at $3.2 billion (changed 0.39% YoY), and the FY2025 full-year result was $3.1 billion, up 10.94% from the prior year.
• Inventory Average for Q1 2026 stood at $3.2 billion, down from $3.2 billion in the prior quarter.
• The five-year high for Inventory Average was $3.2 billion in Q3 2025, with the low at $2.0 billion in Q1 2022.
• Average Inventory Average over 5 years is $2.7 billion, with a median of $2.6 billion recorded in 2024.
• Year-over-year, Inventory Average slipped 3.39% in 2022 and climbed 22.42% in 2023.
• Tracing REGN's Inventory Average over 5 years: stood at $2.4 billion in 2022, then increased by 6.82% to $2.6 billion in 2023, then grew by 18.72% to $3.1 billion in 2024, then climbed by 5.73% to $3.2 billion in 2025, then dropped by 2.34% to $3.2 billion in 2026.
• The last three Inventory Average figures came in at $3.2 billion (Q1 2026), $3.2 billion (Q4 2025), and $3.2 billion (Q3 2025), per Business Quant data.

Peer Comparison